Skip to main content

Table 3 Univariate and multivariate analyses for progression-free and overall survival using the Cox proportional hazard model

From: Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

Variables

PFS

OS

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR (95% CI) P

HR (95% CI) P

HR (95% CI) P

HR (95% CI) P

Age (years)

 <55

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 ≥55

0.99 (0.67–1.44) 0.939

1.33 (0.80–2.20) 0.268

1.14 (0.67–1.92) 0.634

1.51 (0.75–3.04) 0.245

ASA

 1–2

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 3–4

2.29 (1.37–3.84) 0.002

2.38 (1.26–4.51) 0.008

3.12 (1.64–5.90) < 0.001

3.24 (1.54–6.82) 0.009

Baseline CA-125 level (U/ml)

 ≤800

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 >800

1.04 (0.71–1.53) 0.826

1.14 (0.69–1.90) 0.605

0.79 (0.47–1.34) 0.382

0.93 (0.45–1.91) 0.838

FIGO stage

 III

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 IV

0.91 (0.62–1.33) 0.629

0.74 (0.47–1.18) 0.210

0.75 (0.44–1.26) 0.277

0.62 (0.32–1.24) 0.177

Histology

 Others

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Mucinous

2.64 (1.54–4.50) < 0.001

2.31 (1.26–4.24) 0.007

4.69 (2.48–8.85) < 0.001

3.24 (1.54–6.82) 0.002

 Clear cell

2.10 (1.30–3.42) 0.003

1.92 (1.12–3.29) 0.017

2.62 (1.37–4.99) 0.004

2.56 (1.21–5.30) 0.013

Residual disease

 ≤1 cm

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 >1 cm

2.86 (1.75–4.66) < 0.001

2.40 (1.43–4.04) 0.001

3.46 (1.89–6.33) < 0.001

2.43 (1.28–4.63) 0.007

Surgery extent

 Standard

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Radical

0.94 (0.64–1.39) 0.771

1.75 (1.02–2.99) 0.042

0.98 (0.57–1.67) 0.933

1.86 (0.97–3.56) 0.062

LND

 No

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Yes

0.67 (0.17–2.76) 0.004

0.33 (0.18–0.61) < 0.001

0.36 (0.09–1.49) 0.002

0.32 (0.16–0.62) 0.001

LN metastasis

 No

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Yes

1.03 (0.25–4.26) 0.074

2.89 (1.65–5.07) < 0.001

0.46 (0.11–1.97) 0.553

1.78 (0.74–4.32) 0.201

  1. PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists, CA-125 cancer antigen 125, FIGO Federation of Gynecology and Obstetrics, M/C Mucinous/Clear, LND lymph node dissection, LN lymph node